Newslist

Researchers from Würzburg and Marburg identify a long non-coding RNA as a key regulator of macrophages | Study from the Vogel and Westermann labs published in PNAS.

Cyclists from IMIB, HIRI and RVZ accumulated a total of 7,865 kilometers.

Janina Rieger is a member of the junior research group of Dr. Carmen Aguilar, whose work focuses on host-pathogen interactions in the context of urinary tract infection.

In modern medicine, RNA-based therapies are considered promising approaches for preventing, diagnosing, and treating diseases. The rapid development of mRNA vaccines during the COVID-19 pandemic, for example, demonstrated the potential of these technologies.

Camilla Ciolli Mattioli studies the survival strategies of bacteria in host cells. The Biotechnologist is a new group leader at the Helmholtz Institute for RNA-based Infection Research and junior professor at the University of Würzburg.

Minister President Markus Söder has honoured nine personalities with the Bavarian Maximiliansorden. Among them from Würzburg: Professors Georg Ertl and Jörg Vogel.

Study just out in Nature: Vogel lab publishes new RNA technology for phages.

Team from IMIB, HIRI and RVZ way ahead with 240 kilometers per capita

Researchers at HIRI and the Chair of Microbiology at the University of Würzburg have established the connection between cell shape and function of the intestinal inhabitant Bacteroides thetaiotaomicron.

The University of Würzburg has secured funding for two Clusters of Excellence under the Excellence Strategy. One of them is the new NUCLEATE Cluster, which focuses on the innovative field of nucleic acids.

The German National Academy of Sciences Leopoldina has admitted Cynthia Sharma, an infection biologist at the University of Würzburg, to the section ‘Microbiology and Immunology’.

Nearly 80 doctoral students from the HZI (Helmholtz Centre for Infection Research Braunschweig) and the IMIB gathered on October 17 and 18 at the Medical Campus.

The ASOBIOTICS 2024 symposium provided participants with a platform to discuss the challenges of progressing antibacterial ASOs from basic research to clinical application.

The competition for the multi-million euro federal and state funding programme is entering its final phase. JMU has submitted two proposals and the results of the evaluation will be available in May 2025.

Scientists from IMIB, RVZ and HIRI exhibit their creative works